ACT Capital Management has fully exited its position in Structure Therapeutics (NASDAQ: GPCR), selling 38,500 shares valued at approximately $2.63 million during the first quarter of 2026. This decision resulted in a decrease of $2.68 million in the fund’s quarter-end position value, reflecting both the sale and stock price movement. The transaction accounted for 2.07% of ACT’s reported assets under management.
This divestment comes as Structure Therapeutics has seen its shares rise 47% over the past year, outperforming the S&P 500 by 17 percentage points. The company, which focuses on developing oral therapeutics for chronic diseases, recently reported positive Phase 2 data for its GLP-1 drug candidate, indicating strong potential in the obesity treatment market. However, ACT Capital’s exit suggests a strategic move to lock in gains amid ongoing volatility in the biotech sector.
Investors should note that while ACT’s sale may indicate a cautious approach, Structure Therapeutics’ underlying momentum and significant cash reserves position it well for future growth, especially in light of its promising clinical data.
Source: nasdaq.com